NCT03350620 - CHAMP: Study of NVK-002 in Children With Myopia | Biotech Hunter

Enrollment

670

Participants

Timeline

Start Date

November 20, 2017

Primary Completion Date

September 7, 2022

Study Completion Date

October 19, 2023

Conditions

Myopia

Interventions

DRUG

NVK-002 Concentration 1

Study medication will be administered, once daily (QD)

DRUG

NVK-002 Concentration 2

Study medication will be administered, once daily (QD)

DRUG

Placebo

Vehicle (placebo) will be administered, once daily (QD)

Trial Locations (26)

8950

Site #107, Barcelona

10036

Site #002, New York

17601

Site #017, Lancaster

19027

Site #011, Elkins Park

27603

Site #013, Raleigh

32751

Site #004, Maitland

38104

Site #008, Memphis

43210

Site #001, Columbus

53705

Site #021, Madison

61615

Site #024, Peoria

63110

Site #014, St Louis

78240

Site #007, San Antonio

85711

Site #009, Tucson

92129

Site #016, San Diego

92831

Site #003, Fullerton

94720

Site #015, Berkeley

97116

Site #018, Forest Grove

98034

Site #012, Kirkland

99204

Site #020, Spokane

06810

Site #005, Danbury

02115

Site #006, Boston

H - 1085

Site #104, Budapest

D07 H6K8

Site #101, Dublin

3015 AA

Site # 105, Rotterdam

BT52 1HS

Site #103, Coleraine

EC1V 2PD

Site #106, London